Trial 14SK-19-1


Evaluating the PD-1 checkpoint inhibitor, Cemiplimab, as neoadjuvant therapy in high risk localized, locally recurrent, and regionally advanced cutaneous squamous cell carcinoma: a Phase II pilot study

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.
Other Trial Staff:  Cristina De Leon, Coordinator, Chi Nguyen, Coordinator, Maria Sharma, Coordinator, Leila Andres, Coordinator, Fahim Raian, D.M., Edwin Smura, Coordinator, Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Kristy Sartor Massopust, Coordinator, Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Atessa Kiani, Coordinator, Diana Oganyesyan, Coordinator, Janelle Luevano, Coordinator, Ramy Farag, Coordinator, Alda Inveiss, Coordinator, Lauren Wagner, Coordinator, Bomi Choi, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.